Maraviroc in latest Japanese approval recommendations
This article was originally published in Scrip
Executive Summary
Four products for orphan HIV and cancer indications have been recommended for approval in Japan, including Pfizer's novel HIV/AIDS therapy Celsentri (maraviroc).